LLY

900.24

-0.63%↓

JNJ

240.4

+0.51%↑

ABBV

211.46

+2.44%↑

NVS

150.38

+0.61%↑

MRK

119.65

+0.73%↑

LLY

900.24

-0.63%↓

JNJ

240.4

+0.51%↑

ABBV

211.46

+2.44%↑

NVS

150.38

+0.61%↑

MRK

119.65

+0.73%↑

LLY

900.24

-0.63%↓

JNJ

240.4

+0.51%↑

ABBV

211.46

+2.44%↑

NVS

150.38

+0.61%↑

MRK

119.65

+0.73%↑

LLY

900.24

-0.63%↓

JNJ

240.4

+0.51%↑

ABBV

211.46

+2.44%↑

NVS

150.38

+0.61%↑

MRK

119.65

+0.73%↑

LLY

900.24

-0.63%↓

JNJ

240.4

+0.51%↑

ABBV

211.46

+2.44%↑

NVS

150.38

+0.61%↑

MRK

119.65

+0.73%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Fechado

SetorSaúde

3.09 0.98

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.06

Máximo

3.16

Indicadores-chave

By Trading Economics

Rendimento

-15M

-40M

Vendas

8.2M

50M

Margem de lucro

-80.43

Funcionários

435

EBITDA

-19M

-42M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+28.62% upside

Dividendos

By Dow Jones

Próximos Ganhos

11 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

7.8M

1.1B

Abertura anterior

2.11

Fecho anterior

3.09

Sentimento de Notícias

By Acuity

50%

50%

164 / 349 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de mar. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

26 de mar. de 2026, 23:36 UTC

Conversa de Mercado
Notícias Principais

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

26 de mar. de 2026, 23:35 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod Ricard: Confirms Discussions With Brown-Forman

26 de mar. de 2026, 23:29 UTC

Ganhos

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

26 de mar. de 2026, 23:28 UTC

Ganhos

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

26 de mar. de 2026, 23:28 UTC

Ganhos

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

26 de mar. de 2026, 23:28 UTC

Ganhos

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

26 de mar. de 2026, 23:27 UTC

Ganhos

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

26 de mar. de 2026, 23:27 UTC

Ganhos

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

26 de mar. de 2026, 23:08 UTC

Conversa de Mercado

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

26 de mar. de 2026, 23:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

26 de mar. de 2026, 23:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

26 de mar. de 2026, 23:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

26 de mar. de 2026, 23:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

26 de mar. de 2026, 23:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod in Deal Talks With Brown-Forman -- WSJ

26 de mar. de 2026, 22:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

26 de mar. de 2026, 22:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

26 de mar. de 2026, 22:26 UTC

Ganhos

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

26 de mar. de 2026, 22:26 UTC

Ganhos

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

26 de mar. de 2026, 22:26 UTC

Ganhos

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

26 de mar. de 2026, 22:08 UTC

Ganhos

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

26 de mar. de 2026, 22:08 UTC

Ganhos

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

26 de mar. de 2026, 22:08 UTC

Ganhos

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

26 de mar. de 2026, 22:07 UTC

Conversa de Mercado
Notícias Principais

Global Energy Roundup: Market Talk

26 de mar. de 2026, 22:07 UTC

Conversa de Mercado
Notícias Principais

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

26 de mar. de 2026, 22:00 UTC

Ganhos

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

26 de mar. de 2026, 22:00 UTC

Ganhos

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

26 de mar. de 2026, 22:00 UTC

Ganhos

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

26 de mar. de 2026, 21:39 UTC

Aquisições, Fusões, Aquisições de Empresas

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

26 de mar. de 2026, 21:38 UTC

Aquisições, Fusões, Aquisições de Empresas

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Comparação entre Pares

Variação de preço

Maravai LifeSciences Holdings Inc (Class A) Previsão

Preço-alvo

By TipRanks

28.62% parte superior

Previsão para 12 meses

Média 4 USD  28.62%

Máximo 5 USD

Mínimo 3 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Maravai LifeSciences Holdings Inc (Class A) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

3

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

2.02 / 2.115Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

No Evidence

Sentimento

By Acuity

164 / 349 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat